Steven D. Targum
Chief Medical AdvisorDr. Steven D. Targum, also known as Steve, M.D, is Chief Medical Advisor of Alterity Therapeutics Limited (formerly known as Prana Biotechnology Limited). since March 2007. Dr. Targum had been Scientific Director at Signant Health (formerly known as Bracket Global LLC) since June 2015 until 2024. Dr. Targum serves as Acting Chief Medical Officer of BrainCells Inc. He founded Clintara, LLC in 2009 and serves as its Chief Medical Officer. He serves as Chief Medical Officer of MSI Methylation Sciences, Inc. He serves as the Chief Clinical Advisor and Acting Chief Medical Officer of Functional Neuromodulation, Ltd. He served as an Executive-in-Residence at Oxford Bioscience Partners since joining in 2005 until 2011. He serves as a Consultant to the pharmaceutical and venture capital community in the area of CNS drug development. He consults widely to the pharmaceutical industry regarding the design and implementation of clinical trials for new psychotropic drugs and the progression of drug development from concept to approval to launch. He was a Consultant in Psychiatry at the Massachusetts General Hospital from 2005 to 2014. He served as Senior Principal Advisor to UBC-PharmaStar. He established and operated a multi-site clinical trials program in Philadelphia. As Principal Investigator, he conducted over 200 clinical drug trials in therapeutic areas that included anxiety, depression, mania, schizophrenia and Alzheimer's disease. He founded Pharmastar LLC in 2001 and served as its Executive Officer. He served as the Chief Medical Officer of BrainCells Inc. until March 2009, where he worked with the Scientific team to translate the BCI neurogenesis platform into clinical drug development strategies. He is a Lecturer at the Harvard Medical School. He was a Professor of Psychiatry at Hahnemann University School of Medicine in Pennsylvania from 1989 to 1995. In the course of his career, he as a Research Scientist at the National Institute of Mental Health (NIMH); the Medical Director of a psychiatric hospital in Sarasota, Florida, Chairman of the Department of Psychiatry at Crozer-Chester Medical Center located outside of Philadelphia. He served as Vice Chairman of the Department of Mental Health Sciences at Hahnemann University School of Medicine in Pennsylvania from 1989 to 1995. In addition, he owned and directed a large clinical trials practice in Philadelphia where he conducted over 200 pharmaceutical studies across diverse therapeutic areas including major depression, mania, anxiety disorders, schizophrenia and Alzheimer's disease. He serves as the Member of Scientific Advisory Board of Psychiatry of FORUM Pharmaceuticals Inc. He serves as a Member of the Scientific Advisory Board of NuPathe, Inc. He serves as a Member of Scientific Advisory Board - Psychiatry at EnVivo Pharmaceuticals, Inc. He served as a Member of Research and Development Advisory Board at Alterity Therapeutics Limited (formerly known as Prana Biotechnology Limited) since March 22, 2007. He has published over 100 scientific articles the areas of psychopharmacology, Psychobiology and Clinical Trials Methodology and lectured at professional meetings throughout the world. Dr. Targum serves as Member of Clinical Advisory Board at Navitor Pharmaceuticals, Inc. Dr. Targum received his B.A. degree in Biology from Colgate University and his MD from Mount Sinai School of Medicine in New York City.
Positions
- Company NameAlterity Therapeutics LimitedStock CodeATHEPositionChief Medical AdvisorColleagues
- DADavid A. StamlerCEO, MD & Director
- JBJulian BabarczyIndependent Non-Executive Chair
- AMAbby Macnish NivenCFO & Company Secretary
- RERudolph Emile TanziChief Scientific Advisor and Member of Research & Development Advisory Board
- RCRobert ChernyHead of Research
- PAPeter Ashley MarksNon-Executive Independent Director
- ISIra ShoulsonChairman of Research & Development Advisory Board
